title: Pharmacokinetics of guanosine in rats following intravenous or intramuscular administration of a 1:1 mixture of guanosine and acriflavine, a potential antitumor agent.
abstract: A 1:1 mixture of acriflavine (ACF; CAS 8063-24-9) and guanosine is under evaluation in preclinical studies as a possible antitumor agent. Guanosine is known to potentiate the anti-cancer activity of ACF. We therefore investigated the pharmacokinetics of guanosine following administration of the ACF/guanosine mixture in rats. Rats were given guanosine (1 or 5 mg/kg) or ACF/guanosine (2 or 10 mg/kg) by i.v. bolus; or guanosine (3 or 15 mg/kg) or ACF/guanosine (6 or 30 mg/kg) by i.m. injection. We found that guanosine was rapidly cleared from the blood and transferred to tissues after i.m. administration of ACF/guanosine. The mean plasma half-lives (t(1/2)) at the alpha and beta phases were 0.091 and 6.86 h, or 0.09 and 7.51 h at a dose of 1 or 5 mg/kg guanosine, respectively. ACF had no effect on the plasma disappearance of guanosine following either i.v. bolus or i.m. administration of the combination mixture. Moreover, the ACF combination with guanosine did not significantly alter the values of MRT, V(dss), and CL(t) of guanosine. Guanosine exhibited linear pharmacokinetics over the dose range from 1 to 5 mg/kg for i.v. doses and 3 to 15 mg/kg for i.m. doses. The bioavailability of guanosine after i.m. administration was 84% for 3 mg/kg dose and 88% for 15 mg/kg dose. ACF had no effects on biliary and urinary excretion of guanosine after i.m. administration. The cumulative amount of guanosine in urine after i.m. administration was about 5-fold larger than that in bile, indicating that guanosine is mostly excreted into the urine. Guanosine was widely distributed in all tissues examined in this study, but was most highly concentrated in the kidney after i.m. administration, followed by slow excretion to bile or urine. ACF had no effect on the tissue distribution of guanosine following i.m. administration. These characterizations of the pharmacokinetics of guanosine after administration of the ACF/guanosine combination will be useful in providing preclinical and clinical bases for the potential application of this combination to the treatment of cancer.
authors.affiliation: National Research Laboratory of PK/PD, CBITRC, Biotechnology Research Institute, College of Pharmacy, Chungbuk National University, Cheongju, Chungbuk 361-763, Korea.
authors.forename: Dae Hwan
authors.initials: DH
authors.lastname: Shin
authors.forename: Kyu Seok
authors.initials: KS
authors.lastname: Choi
authors.forename: Byung Suk
authors.initials: BS
authors.lastname: Cho
authors.forename: Sukgil
authors.initials: S
authors.lastname: Song
authors.forename: Dong-Cheul
authors.initials: DC
authors.lastname: Moon
authors.forename: Jin Tae
authors.initials: JT
authors.lastname: Hong
authors.forename: Chong-Kil
authors.initials: CK
authors.lastname: Lee
authors.forename: Youn Bok
authors.initials: YB
authors.lastname: Chung
mesh_terms: D000167:Acriflavine; D000818:Animals; D000970:Antineoplastic Agents; D019540:Area Under Curve; D004338:Drug Combinations; D006151:Guanosine / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007202:Indicators and Reagents; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D014018:Tissue Distribution
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D007202:Indicators and Reagents; D006151:Guanosine; D000167:Acriflavine